very interesting thought.

it would explain the "out of the blue" research coverage by Citi. That still confuses me - unless, Citi had to come up to speed on CytoDyn for some specific reason. Otherwise, there is no way on earth that they would randomly pick a pre-revenue OTC biotech to cover.

I would fully support a partnership that would accelerate our path to realizing the potential of this drug.